Study identifier:D3870C00002
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
A Phase I, Single Centre, Single-blind, Randomised, Placebo-controlled, Parallel-group Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD2820 after Administration of Multiple Ascending Doses
obesity
Phase 1
Yes
AZD2820, Placebo
Male
18
Interventional
18 Years - 45 Years
Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Parallel Assignment
Masking: Single Blind
Primary Purpose: Basic Science
Verified 01 Jan 2014 by AstraZeneca
AstraZeneca
-
No locations available
Arms | Assigned Interventions |
---|---|
Active Comparator: AZD2820 AZD2820 multiple injections | Drug: AZD2820 Ascending subcutaneous injections of AZD2820 once daily for 14 days in the abdomen |
Placebo Comparator: Placebo for AZD2820 Placebo for AZD2820 multiple injections | Drug: Placebo Ascending subcutaneous injections of placebo for AZD2820 once daily for 14 days in the abdomen |